Overview

INB03 for the Treatment of Pulmonary Complications From COVID-19

Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Inmune Bio, Inc.